Morgan Stanley downgraded BioAge Labs (BIOA) to Underweight from Overweight with a price target of $5, down from $40. The company discontinued its STRIDES trial following cases of liver transaminitis, which removes the key clinical catalyst for next year, the analyst tells investors in a research note. The firm downgraded shares on a relative basis as it sees better opportunities elsewhere for 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio